Pharmaceuticals Australia

Australia Lp(a) Targeted Therapies Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Lp(a) Targeted Therapies Market Industry Trends and Forecast to 2034: Segmented by (Drug Type, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $1.0 Mn Placeholder estimate
Estimate 2025 $1.6 Mn 1.2% of the global market
Projected 2034 $114.6 Mn 7,250% Adds $113.0 Mn over 9 forecast years
CAGR 2025–2034 61.2% Faster than 100% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.22% of the global market.
  • In APAC, the largest is China at $10.9 Mn.
  • Fastest growing: India at 63.2% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$113.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Lp(a) Targeted Therapies Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $1.0 Mn — —
2025 (base) $1.6 Mn +$0.6 Mn —
2026 (forecast) $2.5 Mn +$1.0 Mn +61.2%
2027 (forecast) $4.1 Mn +$1.5 Mn +159.9%
2028 (forecast) $6.5 Mn +$2.5 Mn +318.9%
2029 (forecast) $10.5 Mn +$4.0 Mn +575.2%
2030 (forecast) $17.0 Mn +$6.4 Mn +988.5%
2031 (forecast) $27.4 Mn +$10.4 Mn +1,654.6%
2032 (forecast) $44.1 Mn +$16.7 Mn +2,728.5%
2033 (forecast) $71.1 Mn +$27.0 Mn +4,459.5%
2034 (forecast) $114.6 Mn +$43.5 Mn +7,250%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Lp(a) Targeted Therapies Market Analysis at a glance
Market size, 2025$1.6 Mn placeholder estimate
Forecast, 2034$114.6 Mn placeholder estimate
Growth (CAGR), 2025–203461.2% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug type, indication and end user (see all)
Key playersNovartis AG, Amgen Inc., Eli Lilly and Company, Silence Therapeutics, Ionis Pharmaceuticals (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials13 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Lp(a) Targeted Therapies Market Analysis Executive Summary

Lp(a) targeted therapies lower lipoprotein(a), an inherited risk factor for heart disease that current cholesterol drugs do not treat well.

Key segments of the lp(a) Targeted Therapies market include drug type (Antisense Oligonucleotides, siRNA and Oral Small Molecules) and indication (Cardiovascular Event Prevention and Aortic Valve Stenosis).

Bar chart: Australia Lp(a) Targeted Therapies market size, 2024–2034, placeholder estimates. $1.0 Mn in 2024, $1.6 Mn in 2025 and $114.6 Mn in 2034, 61.2% CAGR.
Australia Lp(a) Targeted Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Lp(a) Targeted Therapies Market Dynamics

Market Growth Drivers

Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the lp(a) Targeted Therapies market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.

Opportunity

Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the lp(a) Targeted Therapies market, especially in fast-growing emerging economies.

Market Restraints

High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the lp(a) Targeted Therapies market. Long-term safety data and lifestyle support are still needed for many patients.

Competitive Landscape for Lp(a) Targeted Therapies Market in Australia

The lp(a) Targeted Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Lp(a) Targeted Therapies Market in Australia

Lp(a) Targeted Therapies in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 13 studies on Lp(a) Targeted Therapies that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for lp(a) Targeted Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Lp(a) Targeted Therapies right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Lp(a) Targeted Therapies in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Lp(a) Targeted Therapies market in Australia?
Placeholder estimate: about $1.6 Mn in 2025, rising to about $114.6 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Lp(a) Targeted Therapies market in Australia growing?
Placeholder estimate: about 61.2% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Lp(a) Targeted Therapies market report cover?
The report splits the market by drug type (Antisense Oligonucleotides, siRNA, Oral Small Molecules), indication (Cardiovascular Event Prevention, Aortic Valve Stenosis) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Lp(a) Targeted Therapies market?
Key players include Novartis AG, Amgen Inc., Eli Lilly and Company, Silence Therapeutics and Ionis Pharmaceuticals.
What is driving the Lp(a) Targeted Therapies market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the lp(a) Targeted Therapies market.
Who regulates Lp(a) Targeted Therapies in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Lp(a) Targeted Therapies are running in Australia?
13 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Lp(a) Targeted Therapies?
PubMed lists 93 papers on Lp(a) Targeted Therapies added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on cardiovascular

See the topic